US patent for cell therapy kit:
This article was originally published in Clinica
Executive Summary
Stem cell therapy pioneer Aastrom Biosciences has received a US patent covering its automated equipment for producing patient-specific cell therapy products. The Ann Arbor, Michigan-based company's AastromReplicell system, which is marketed in Europe but is not yet available in the US, is an instrumentation platform that can operate a family of patient-specific cell therapy kits.